Genzyme’s Alemtuzumab for Multiple Sclerosis Shows Durable Treatment Benefit in Review of Four-Year Phase 2 Trial Data
Posted Nov 17 2009 10:20pm
Genzyme Corporation(Nasdaq: GENZ) reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab.
The CAMMS223 Phase 2 trial compared alemtuzumab to an approved MS therapy Rebif®(interferon beta-1a) in early, relapsing-remitting multiple sclerosis (RRMS) patients who had received no prior therapy. The accumulated four-year efficacy and safety data from the Phase 2 trial will be presented today in Germany at theEuropean Committee for Treatment and Research in Multiple Sclerosis(ECTRIMS) annual meeting, one of the largest annual international MS conferences. Three-year CAMMS223 trial data were reported in theNew England Journal of Medicine(NEJM) last October.
"These longer-term Phase 2 data showed durable reductions in the occurrence of relapses and the accumulation of disability, extending for several years after patients’ last treatment,” said Alasdair Coles, MD, Senior Lecturer, Department of Clinical Neurosciences, University of Cambridge, a lead investigator of the Phase 2 clinical trial. "These findings confirm the extended duration of response observed in our pilot studies with alemtuzumab in patients with relapsing MS.”